Moreadith Randall 4

What Happened Moreadith Randall, Chief Scientific Officer of Serina Therapeutics (SER), exercised 39,000 stock options on March 19, 2026 at $0.06 per share (total cost $2,340) and immediately sold 39,000 shares in an open-market transaction at $2.50 per share, generating $97,500. The Form 4 also reports a derivative disposition for 39,000 shares at $0.00, which is the filing’s separate reporting of the option conversion/exercise.

Key Details

• Transaction date: 2026-03-19 (reported on Form 4 filed 2026-03-20).
• Exercises: 39,000 shares acquired at $0.06 each (total cash paid $2,340).
• Sale: 39,000 shares sold in open market at $2.50 each (proceeds $97,500).
• Derivative line: 39,000 shares listed as a derivative disposition at $0.00 (reported separately).
• Shares owned after transaction: not disclosed in the filing.
• Footnote: F1 — the stock options exercised were fully vested.
• Timeliness: Filing appears timely (transaction date 3/19/2026; Form 4 filed 3/20/2026).

Context This sequence—exercising vested options and selling the resulting shares the same day—is commonly a cashless exercise (the insider converts options into shares and sells them to cover costs or take proceeds). The sale is routine reporting of insider liquidity and should not be read as a direct signal of company prospects; motivations are not disclosed.